Alteogen (196170.KQ) Stock Price

Alteogen Price

KOSDAQ·CLOSED
241,500.00
​
Market closed

Over the last 13 years Alteogen grew revenue by 36.0% annually, reaching 215.86 B KRW. Earnings per share have grown at 20.3% per year over the last 13 years. For Alteogen, the net margin of 65.6% is up versus 14.6% a few years ago. The consensus 12-month price target for Alteogen is 469,200.00 KRW, about 94.3% above where the stock trades today. Of 10 analysts, 8 rate the stock a buy — an overall Buy consensus.

Alteogen stock price

Access this data via the Eulerpool API

Alteogen business model & stock analysis

Alteogen, Inc. engages in the development, manufacture, and sale of biopharmaceuticals and anticancer drugs. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2014-12-12. The firm operates biobetter business segment, which develops protein pharmaceuticals and cancer therapies, and bio similar business segment, which develops bio similar and animal medicines. The firm mainly provides growth hormone, herceptin, humira, antibodies, animal drugs and others.

Frequently asked questions about Alteogen

Analysts currently set an average price target of 446,250.00 KRW for the Alteogen stock (median: 469,200.00 KRW), implying +84.8 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the Alteogen stock: 8 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Alteogen to generate revenue of 470.00 B KRW and earnings per share of 4,246.66 KRW.

Converted at the current exchange rate, the Alteogen share trades at 160.59 EUR (241,500.00 KRW).

The Alteogen share (196170.KQ) is listed on 1 stock exchanges, including: KOSDAQ (Seoul) (196170.KQ).

The expected revenue of Alteogen is 470.00 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Alteogen is 227.12 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Alteogen is currently 56.87. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alteogen stock.

The price-to-sales ratio (P/S) of Alteogen is currently 27.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Alteogen stock.

The Eulerpool Quality Score for Alteogen is 5/10.

The ISIN of Alteogen is KR7196170005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Alteogen is 196170.KQ. The ticker symbol is used to trade Alteogen shares on the stock exchange.

Fair ValueTerminal
198,030.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website alteogen.com
Country
South Korea
Currency
KRW
Initial public offering
Dec 12, 2014
ISIN
KR7196170005
Cusip
Y0R93X109
Market capitalization
12.93 T KRWMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
56.92
P/Ee 2027
44.27
P/Se
27.48
EV/EBIT
120.35
P/B Ratio
29.04
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
31.54 %
Last updated Oct 10, 2026, 2:40 PM

Alteogen Peer Group

Alteogen Ticker

KOSDAQ · 196170.KQ

Alteogen FIGI

196170:KS · BBG007H0XZW6196170:KQ · BBG007H0XZY419617KRW:EO · BBG01BTX6B8119617KRW:X2 · BBG01BTX6B9019617KRW:XH · BBG01BTX6BC619617KRW:XF · BBG01BTX6BF319617KRW:XE · BBG01BTX6BH119617KRW:XJ · BBG01BTX6BJ919617KRW:XL · BBG01BTX6BK719617KRW:XG · BBG01BTX6BL619617KRW:XO · BBG01BTX6BM519617KRW:XA · BBG01BTX6BR0

All fundamentals and in-depth analysis of Alteogen

Our stock analysis for Alteogen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alteogen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.